vs
EXACT SCIENCES CORP（EXAS）与Dave & Buster's Entertainment, Inc.（PLAY）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Dave & Buster's Entertainment, Inc.的2.0倍（$878.4M vs $448.2M），Dave & Buster's Entertainment, Inc.净利率更高（-9.4% vs -9.8%，领先0.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs -1.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-20.6M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -13.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
戴夫与巴斯特娱乐是总部位于美国达拉斯的餐饮娱乐企业，旗下每家门店都配备全套服务餐厅、酒吧以及名为“百万美元 midway”的游戏游乐区。截至2024年2月，该公司共开设162家门店，其中美国本土158家，波多黎各和加拿大各设2家门店，主打餐饮与休闲娱乐融合的消费体验。
EXAS vs PLAY — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $448.2M |
| 净利润 | $-86.0M | $-42.1M |
| 毛利率 | 70.1% | 85.8% |
| 营业利润率 | -9.4% | -3.6% |
| 净利率 | -9.8% | -9.4% |
| 营收同比 | 23.1% | -1.1% |
| 净利润同比 | 90.1% | -28.7% |
| 每股收益（稀释后） | $-0.45 | $-1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $448.2M | ||
| Q3 25 | $850.7M | $557.4M | ||
| Q2 25 | $811.1M | $567.7M | ||
| Q1 25 | $706.8M | $534.5M | ||
| Q4 24 | $713.4M | $453.0M | ||
| Q3 24 | $708.7M | $557.1M | ||
| Q2 24 | $699.3M | $588.1M | ||
| Q1 24 | $637.5M | $599.0M |
| Q4 25 | $-86.0M | $-42.1M | ||
| Q3 25 | $-19.6M | $11.4M | ||
| Q2 25 | $-1.2M | $21.7M | ||
| Q1 25 | $-101.2M | $9.3M | ||
| Q4 24 | $-864.6M | $-32.7M | ||
| Q3 24 | $-38.2M | $40.3M | ||
| Q2 24 | $-15.8M | $41.4M | ||
| Q1 24 | $-110.2M | $36.1M |
| Q4 25 | 70.1% | 85.8% | ||
| Q3 25 | 68.6% | 86.3% | ||
| Q2 25 | 69.3% | 85.5% | ||
| Q1 25 | 70.8% | 85.5% | ||
| Q4 24 | 69.0% | 85.0% | ||
| Q3 24 | 69.4% | 85.3% | ||
| Q2 24 | 69.8% | 85.2% | ||
| Q1 24 | 70.0% | 84.1% |
| Q4 25 | -9.4% | -3.6% | ||
| Q3 25 | -3.0% | 9.5% | ||
| Q2 25 | -0.3% | 11.1% | ||
| Q1 25 | -13.6% | 8.3% | ||
| Q4 24 | -122.8% | 1.4% | ||
| Q3 24 | -5.6% | 15.2% | ||
| Q2 24 | -3.8% | 14.5% | ||
| Q1 24 | -16.7% | 14.9% |
| Q4 25 | -9.8% | -9.4% | ||
| Q3 25 | -2.3% | 2.0% | ||
| Q2 25 | -0.1% | 3.8% | ||
| Q1 25 | -14.3% | 1.7% | ||
| Q4 24 | -121.2% | -7.2% | ||
| Q3 24 | -5.4% | 7.2% | ||
| Q2 24 | -2.3% | 7.0% | ||
| Q1 24 | -17.3% | 6.0% |
| Q4 25 | $-0.45 | $-1.22 | ||
| Q3 25 | $-0.10 | $0.32 | ||
| Q2 25 | $-0.01 | $0.62 | ||
| Q1 25 | $-0.54 | $0.32 | ||
| Q4 24 | $-4.69 | $-0.84 | ||
| Q3 24 | $-0.21 | $0.99 | ||
| Q2 24 | $-0.09 | $0.99 | ||
| Q1 24 | $-0.60 | $0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $13.6M |
| 总债务越低越好 | — | $1.6B |
| 股东权益账面价值 | $2.4B | $130.8M |
| 总资产 | $5.9B | $4.1B |
| 负债/权益比越低杠杆越低 | — | 12.17× |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $13.6M | ||
| Q3 25 | $1.0B | $12.0M | ||
| Q2 25 | $858.4M | $11.9M | ||
| Q1 25 | $786.2M | $6.9M | ||
| Q4 24 | $1.0B | $8.6M | ||
| Q3 24 | $1.0B | $13.1M | ||
| Q2 24 | $946.8M | $32.1M | ||
| Q1 24 | $652.1M | $37.3M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | $2.4B | $130.8M | ||
| Q3 25 | $2.5B | $166.2M | ||
| Q2 25 | $2.5B | $146.8M | ||
| Q1 25 | $2.4B | $145.8M | ||
| Q4 24 | $2.4B | $226.6M | ||
| Q3 24 | $3.2B | $284.4M | ||
| Q2 24 | $3.2B | $292.5M | ||
| Q1 24 | $3.1B | $251.2M |
| Q4 25 | $5.9B | $4.1B | ||
| Q3 25 | $5.9B | $4.1B | ||
| Q2 25 | $5.8B | $4.1B | ||
| Q1 25 | $5.7B | $4.0B | ||
| Q4 24 | $5.9B | $3.9B | ||
| Q3 24 | $6.7B | $3.8B | ||
| Q2 24 | $6.7B | $3.8B | ||
| Q1 24 | $6.4B | $3.8B |
| Q4 25 | — | 12.17× | ||
| Q3 25 | — | 9.57× | ||
| Q2 25 | — | 10.98× | ||
| Q1 25 | — | 10.45× | ||
| Q4 24 | — | 6.58× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | 4.58× | ||
| Q1 24 | — | 5.33× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $58.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-20.6M |
| 自由现金流率自由现金流/营收 | 13.7% | -4.6% |
| 资本支出强度资本支出/营收 | 3.6% | 17.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-195.6M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $58.0M | ||
| Q3 25 | $219.9M | $34.0M | ||
| Q2 25 | $89.0M | $95.8M | ||
| Q1 25 | $30.8M | $108.9M | ||
| Q4 24 | $47.1M | $-7.2M | ||
| Q3 24 | $138.7M | $101.8M | ||
| Q2 24 | $107.1M | $108.8M | ||
| Q1 24 | $-82.3M | $97.2M |
| Q4 25 | $120.4M | $-20.6M | ||
| Q3 25 | $190.0M | $-55.2M | ||
| Q2 25 | $46.7M | $-58.8M | ||
| Q1 25 | $-365.0K | $-61.0M | ||
| Q4 24 | $10.7M | $-138.4M | ||
| Q3 24 | $112.6M | $-14.3M | ||
| Q2 24 | $71.2M | $-4.2M | ||
| Q1 24 | $-120.0M | $-25.4M |
| Q4 25 | 13.7% | -4.6% | ||
| Q3 25 | 22.3% | -9.9% | ||
| Q2 25 | 5.8% | -10.4% | ||
| Q1 25 | -0.1% | -11.4% | ||
| Q4 24 | 1.5% | -30.6% | ||
| Q3 24 | 15.9% | -2.6% | ||
| Q2 24 | 10.2% | -0.7% | ||
| Q1 24 | -18.8% | -4.2% |
| Q4 25 | 3.6% | 17.5% | ||
| Q3 25 | 3.5% | 16.0% | ||
| Q2 25 | 5.2% | 27.2% | ||
| Q1 25 | 4.4% | 31.8% | ||
| Q4 24 | 5.1% | 29.0% | ||
| Q3 24 | 3.7% | 20.8% | ||
| Q2 24 | 5.1% | 19.2% | ||
| Q1 24 | 5.9% | 20.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.98× | ||
| Q2 25 | — | 4.41× | ||
| Q1 25 | — | 11.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.53× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PLAY
| Game Play Credit Usage | $273.1M | 61% |
| Food And Nonalcoholic Beverages | $115.1M | 26% |
| Alcoholic Beverage | $53.7M | 12% |
| Other Entertainment | $6.3M | 1% |
| Gift Card Revenue | $3.5M | 1% |
